We are leaders in CRISPR/Cas9 gene targeting. Our fees are low, and our success rates are high. New transgenic and targeted mice that we have created are featured in over 300 publications. We are supported by the Case Western Reserve University School of Medicine the Case Comprehensive Cancer Center, the Clinical and Translational Science Collaborative, the Research Institute for Children's Health and by grants from the NIH, the Cystic Fibrosis Foundation and JobsOhio. We are a component of the FIND Pipeline, which translates gene-directed approaches into therapies for inherited disease.